Skip to content

SG&A at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$6.03B+18.0%
Staar Surgical logo
Staar SurgicalSTAA
$60.88M-28.7%
Bausch + Lomb logo
Bausch + LombBLCO
$544M-3.4%
ClearPoint Neuro logo
ClearPoint NeuroCLPT
$5M+22.4%
IAR
Integra LifeSciencesIART
$178.24M-1.8%
ITG
Integer HoldingsITGR
$58.71M+14.8%

Other financials

Income statement

See full
Revenue$13.4M-5.2%
Gross profit$6.4M-10.4%
Operating income$2.2M+139%
Net income$36.3M+233%
EPS (diluted)$0.00+100%

Balance sheet

See full
Cash & equivalents$12.5M-36.1%
Total debt$7.6M+206%
Total equity$10.8M+149%
Total assets$66.2M-9.2%

Cash flow

See full
Operating cash flow-$4.3M+38.4%
CapEx$77.0K-31.9%
Free cash flow-

Valuation

See full
Market cap$70.13M-53.1%
Enterprise value$65.21M-54.9%
P/E2.4×
P/S1.2×-1.3×

Profitability

See full
Gross margin45.7%-2.1pp
Operating margin-28.7%+7.3pp
Net margin50.9%+30.7pp
FCF margin-26.6%

Returns & leverage

See full
Return on equity-164%-235pp
Debt / equity0.7×
Current ratio2.4×+0.6×

Where this comes from

Reported directly by LENSAR, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: LENSAR, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about LENSAR, Inc.'s sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LENSAR, Inc.'s SG&A?
LENSAR, Inc. (LNSR) reported SG&A of $2.53M in Q1 2026.
How has LENSAR, Inc.'s SG&A changed year-over-year?
LENSAR, Inc.'s SG&A decreased by 77.3% year-over-year, from $11.15M to $2.53M.
What is the long-term trend for LENSAR, Inc.'s SG&A?
Over 4 years (2021 to 2025), LENSAR, Inc.'s SG&A has grown at a 17.3% compound annual growth rate (CAGR), from $23.89M to $45.16M.
What does SG&A mean?
Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.